A view of the Merck & Co. campus in Linden, N.J., on March 9, 2009. Jeff Zelevansky/ReutersBiotech giant Merck announced plans on Nov. 14 to acquire Cidara Therapeutics for $9.2 billion to develop medications for the prevention of influenza.In a company statement, Merck Chairman and CEO Robert Davis said the deal will enable the company to augment its pharmaceuticals with CD388, a long-acting antiviral designed to prevent influenza in individuals at high risk of complications.
-10.9
C
Ottawa
Tuesday, January 20, 2026
The Alliance Press is the world leader in online chained news and information and seeks to inform, engage and empower the world. We expose the information that wasn't known before or current events broadcast over the radio, television, online or in print media. Our content is now available through your mobile phone. No matter where your on-the-go lifestyle takes you, TAP brings the news directly to you.
More from CN
Contact
© The Alliance Media Group design by CODEUS